New Horizons in the Diagnosis & Management of
Idiopathic Pulmonary Fibrosis (IPF)

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Spring Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 25, 2017 to August 1, 2018

Instructions for CME/CNE: Complete the pre test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This educational activity is supported by an educational grant from
Boehringer Ingelheim Pharmaceuticals

Idiopathic pulmonary fibrosis (IPF) is a lung disease that results from the formation of scar tissue deep inside the lungs. It is the most common of the idiopathic interstitial pneumonias, and is a devastating disease associated with irreversible destruction of the lung. The condition is more common in men than in women, and its frequency increases with age between 40 and 70 years. IPF typically has a poor prognosis and the median survival rate is less than four years or fewer from diagnosis. Most patients with idiopathic pulmonary fibrosis present with a gradual onset, which makes it difficult to diagnosis early. Strong awareness of guidelines and the current criteria still makes the diagnostic process difficult to obtain as well as incomplete. It must start with the elicitation of a thorough and extensive medical history that should include review of symptoms or signs suggestive of a systemic disorder, occupational and environmental exposures, use of medications and drugs, and family medical history. Treatment strategies for IPF aim at managing the symptoms and slowing disease progression to best maintain a patient’s quality of life. Guideline recommendations for treatments include nintedanib, which is a tyrosine kinase inhibitor that targets multiple tyrosine kinases, and pirfenidone. Along with these treatments, the standard of care for IPF includes oxygen supplementation, management of co-morbidities, and lung transplants.

Upon Completion of this activity, participants will be able to:

  • Assess and apply guideline recommendations for the diagnosis and management of patients with IPF

  • Discuss the clinical trial data for the efficacy and safety of available and emerging therapies for IPF, including nintedanib and pirfenidone

  • Identify and contrast the appropriate pharmacologic therapy to reflect current guidelines and data

  • Explore a multidisciplinary team approach for IPF to improve patient outcomes

  • Analyze the different adverse effects in patients with IPF and how best to manage them through optimal patient education

Faculty: Leann L. Silhan, MD
Assistant Professor
Division of Pulmonary and Critical Care Medicine
Department of Medicine
Johns Hopkins University School of Medicine


Dr. Silhan serves as a consultant to Boehringer Ingelheim. Her presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Jacquelyn Smith has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation

The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM. Each physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This educational activity is supported by an educational grant from
Boehringer Ingelheim Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue